17.03.2025
Publications category: PBPK/PBBM
17.03.2025
Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report
03.03.2025
Model-informed drug development of flucytosine sustained release formulation in the treatment of cryptococcal meningitis: A case study using PBPK modeling
11.11.2024
Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case study
11.10.2024
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space
20.09.2024
Bioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitis
08.07.2024
Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia
25.06.2024
Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology framework
25.06.2024
Development of a PBPK model to predict monoclonal antibody pharmacokinetics and bioavailability following subcutaneous administration
25.06.2024
Physiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation.
25.06.2024